APO Research
Talk to an analyst

APO RESEARCH · REPORT

Somatostatin Analogs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Somatostatin Analogs Market Outlook and Growth Opportunities 2026

22 December 2025197 pages

Choose your research edition.

Industry ResearchSomatostatin Analogs Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Somatostatin Analogs Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Somatostatin Analogs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Somatostatin Analogs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Somatostatin Analogs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Somatostatin Analogs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Somatostatin Analogs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Somatostatin Analogs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Somatostatin Analogs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Somatostatin Analogs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Somatostatin Analogs market include Novartis, Peptron, Ipsen Biopharmaceutical and Chiasma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Somatostatin Analogs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Somatostatin Analogs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Somatostatin Analogs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Somatostatin Analogs market size, projected growth trends, production technologies, key applications, and end-use industries.

Somatostatin Analogs Segment by Company

Novartis

Peptron

Ipsen Biopharmaceutical

Chiasma

Somatostatin Analogs Segment by Type

Pasireotide

Lanreotide

Octreotide

Somatostatin Analogs Segment by Application

Acromegaly

Neuroendocrine Tumor

Cushing Syndrome

Carcinoid Syndrome

Others

Somatostatin Analogs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Somatostatin Analogs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Somatostatin Analogs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Somatostatin Analogs significant trends, drivers, influence factors in global and regions.

6. To analyze Somatostatin Analogs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Somatostatin Analogs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Somatostatin Analogs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Somatostatin Analogs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Somatostatin Analogs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Somatostatin Analogs industry.

Chapter 3: Detailed analysis of Somatostatin Analogs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Somatostatin Analogs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Somatostatin Analogs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Somatostatin Analogs Industry Trends Table 2. Somatostatin Analogs Industry Drivers Table 3. Somatostatin Analogs Industry Opportunities and Challenges Table 4. Somatostatin Analogs Industry Restraints Table 5. Global Somatostatin Analogs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Somatostatin Analogs Revenue Share by Company (2021-2026) Table 7. Global Somatostatin Analogs Sales Volume by Company (k units) & (2021-2026) Table 8. Global Somatostatin Analogs Sales Volume Share by Company (2021-2026) Table 9. Global Somatostatin Analogs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Somatostatin Analogs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Somatostatin Analogs Key Company Manufacturing Base & Headquarters Table 12. Global Somatostatin Analogs Company, Product Type & Application Table 13. Global Somatostatin Analogs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Somatostatin Analogs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Pasireotide Table 18. Significant Companies of Lanreotide Table 19. Significant Companies of Octreotide Table 20. Global Somatostatin Analogs Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Somatostatin Analogs Sales Volume by Type (2021-2026) & (k units) Table 22. Global Somatostatin Analogs Sales Volume by Type (2027-2032) & (k units) Table 23. Global Somatostatin Analogs Sales Volume Share by Type (2021-2026) Table 24. Global Somatostatin Analogs Sales Volume Share by Type (2027-2032) Table 25. Global Somatostatin Analogs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Somatostatin Analogs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Somatostatin Analogs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Somatostatin Analogs Sales Value Share by Type (2021-2026) Table 29. Global Somatostatin Analogs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Acromegaly Table 31. Significant Companies of Neuroendocrine Tumor Table 32. Significant Companies of Cushing Syndrome Table 33. Significant Companies of Carcinoid Syndrome Table 34. Significant Companies of Others Table 35. Global Somatostatin Analogs Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 36. Global Somatostatin Analogs Sales Volume by Application (2021-2026) & (k units) Table 37. Global Somatostatin Analogs Sales Volume by Application (2027-2032) & (k units) Table 38. Global Somatostatin Analogs Sales Volume Share by Application (2021-2026) Table 39. Global Somatostatin Analogs Sales Volume Share by Application (2027-2032) Table 40. Global Somatostatin Analogs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Somatostatin Analogs Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Somatostatin Analogs Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Somatostatin Analogs Sales Value Share by Application (2021-2026) Table 44. Global Somatostatin Analogs Sales Value Share by Application (2027-2032) Table 45. Global Somatostatin Analogs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 46. Global Somatostatin Analogs Sales by Region (2021-2026) & (k units) Table 47. Global Somatostatin Analogs Sales Market Share by Region (2021-2026) Table 48. Global Somatostatin Analogs Sales by Region (2027-2032) & (k units) Table 49. Global Somatostatin Analogs Sales Market Share by Region (2027-2032) Table 50. Global Somatostatin Analogs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Somatostatin Analogs Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Somatostatin Analogs Sales Value Share by Region (2021-2026) Table 53. Global Somatostatin Analogs Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Somatostatin Analogs Sales Value Share by Region (2027-2032) Table 55. Global Somatostatin Analogs Market Average Price (US$/unit) by Region (2021-2026) Table 56. Global Somatostatin Analogs Market Average Price (US$/unit) by Region (2027-2032) Table 57. Global Somatostatin Analogs Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Global Somatostatin Analogs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Somatostatin Analogs Sales by Country (2021-2026) & (k units) Table 60. Global Somatostatin Analogs Sales Market Share by Country (2021-2026) Table 61. Global Somatostatin Analogs Sales by Country (2027-2032) & (k units) Table 62. Global Somatostatin Analogs Sales Market Share by Country (2027-2032) Table 63. Global Somatostatin Analogs Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Somatostatin Analogs Sales Value Market Share by Country (2021-2026) Table 65. Global Somatostatin Analogs Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Somatostatin Analogs Sales Value Market Share by Country (2027-2032) Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Somatostatin Analogs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Novartis Somatostatin Analogs Product Portfolio Table 71. Novartis Recent Development Table 72. Peptron Company Information Table 73. Peptron Business Overview Table 74. Peptron Somatostatin Analogs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Peptron Somatostatin Analogs Product Portfolio Table 76. Peptron Recent Development Table 77. Ipsen Biopharmaceutical Company Information Table 78. Ipsen Biopharmaceutical Business Overview Table 79. Ipsen Biopharmaceutical Somatostatin Analogs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Ipsen Biopharmaceutical Somatostatin Analogs Product Portfolio Table 81. Ipsen Biopharmaceutical Recent Development Table 82. Chiasma Company Information Table 83. Chiasma Business Overview Table 84. Chiasma Somatostatin Analogs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Chiasma Somatostatin Analogs Product Portfolio Table 86. Chiasma Recent Development Table 87. Key Raw Materials Table 88. Raw Materials Key Suppliers Table 89. Somatostatin Analogs Distributors List Table 90. Somatostatin Analogs Customers List Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Somatostatin Analogs Product Image Figure 2. Global Somatostatin Analogs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Somatostatin Analogs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Somatostatin Analogs Sales (2021-2032) & (k units) Figure 5. Global Somatostatin Analogs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Somatostatin Analogs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Pasireotide Image Figure 10. Lanreotide Image Figure 11. Octreotide Image Figure 12. Global Somatostatin Analogs Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Somatostatin Analogs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Somatostatin Analogs Sales Volume Share by Type (2021-2032) Figure 15. Global Somatostatin Analogs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Somatostatin Analogs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Somatostatin Analogs Sales Value Share by Type (2021-2032) Figure 18. Acromegaly Image Figure 19. Neuroendocrine Tumor Image Figure 20. Cushing Syndrome Image Figure 21. Carcinoid Syndrome Image Figure 22. Others Image Figure 23. Global Somatostatin Analogs Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Somatostatin Analogs Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Somatostatin Analogs Sales Volume Share by Application (2021-2032) Figure 26. Global Somatostatin Analogs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Somatostatin Analogs Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Somatostatin Analogs Sales Value Share by Application (2021-2032) Figure 29. Global Somatostatin Analogs Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 30. Global Somatostatin Analogs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Somatostatin Analogs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Somatostatin Analogs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Somatostatin Analogs Sales Value (2021-2032) & (US$ Million) Figure 34. North America Somatostatin Analogs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Somatostatin Analogs Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Somatostatin Analogs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Somatostatin Analogs Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Somatostatin Analogs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Somatostatin Analogs Sales Value (2021-2032) & (US$ Million) Figure 40. South America Somatostatin Analogs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Somatostatin Analogs Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Somatostatin Analogs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Somatostatin Analogs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Somatostatin Analogs Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Somatostatin Analogs Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Pasireotide
  • Lanreotide
  • Octreotide
Applications
  • Acromegaly
  • Neuroendocrine Tumor
  • Cushing Syndrome
  • Carcinoid Syndrome
  • Others
Companies covered
  • Novartis
  • Peptron
  • Ipsen Biopharmaceutical
  • Chiasma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Somatostatin Analogs Sales Value (2021-2032)
  4. 1.2.2 Global Somatostatin Analogs Sales Volume (2021-2032)
  5. 1.2.3 Global Somatostatin Analogs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Somatostatin Analogs Market Dynamics
  1. 2.1 Somatostatin Analogs Industry Trends
  2. 2.2 Somatostatin Analogs Industry Drivers
  3. 2.3 Somatostatin Analogs Industry Opportunities and Challenges
  4. 2.4 Somatostatin Analogs Industry Restraints
3 Somatostatin Analogs Market by Company
  1. 3.1 Global Somatostatin Analogs Company Revenue Ranking in 2025
  2. 3.2 Global Somatostatin Analogs Revenue by Company (2021-2026)
  3. 3.3 Global Somatostatin Analogs Sales Volume by Company (2021-2026)
  4. 3.4 Global Somatostatin Analogs Average Price by Company (2021-2026)
  5. 3.5 Global Somatostatin Analogs Company Ranking (2024-2026)
  6. 3.6 Global Somatostatin Analogs Company Manufacturing Base and Headquarters
  7. 3.7 Global Somatostatin Analogs Company Product Type and Application
  8. 3.8 Global Somatostatin Analogs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Somatostatin Analogs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Somatostatin Analogs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Somatostatin Analogs Market by Type
  1. 4.1 Somatostatin Analogs Type Introduction
  2. 4.1.1 Pasireotide
  3. 4.1.2 Lanreotide
  4. 4.1.3 Octreotide
  5. 4.2 Global Somatostatin Analogs Sales Volume by Type
  6. 4.2.1 Global Somatostatin Analogs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Somatostatin Analogs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Somatostatin Analogs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Somatostatin Analogs Sales Value by Type
  10. 4.3.1 Global Somatostatin Analogs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Somatostatin Analogs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Somatostatin Analogs Sales Value Share by Type (2021-2032)
5 Somatostatin Analogs Market by Application
  1. 5.1 Somatostatin Analogs Application Introduction
  2. 5.1.1 Acromegaly
  3. 5.1.2 Neuroendocrine Tumor
  4. 5.1.3 Cushing Syndrome
  5. 5.1.4 Carcinoid Syndrome
  6. 5.1.5 Others
  7. 5.2 Global Somatostatin Analogs Sales Volume by Application
  8. 5.2.1 Global Somatostatin Analogs Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Somatostatin Analogs Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Somatostatin Analogs Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Somatostatin Analogs Sales Value by Application
  12. 5.3.1 Global Somatostatin Analogs Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Somatostatin Analogs Sales Value by Application (2021-2032)
  14. 5.3.3 Global Somatostatin Analogs Sales Value Share by Application (2021-2032)
6 Somatostatin Analogs Regional Sales and Value Analysis
  1. 6.1 Global Somatostatin Analogs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Somatostatin Analogs Sales by Region (2021-2032)
  3. 6.2.1 Global Somatostatin Analogs Sales by Region: 2021-2026
  4. 6.2.2 Global Somatostatin Analogs Sales by Region (2027-2032)
  5. 6.3 Global Somatostatin Analogs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Somatostatin Analogs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Somatostatin Analogs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Somatostatin Analogs Sales Value by Region (2027-2032)
  9. 6.5 Global Somatostatin Analogs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Somatostatin Analogs Sales Value (2021-2032)
  12. 6.6.2 North America Somatostatin Analogs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Somatostatin Analogs Sales Value (2021-2032)
  15. 6.7.2 Europe Somatostatin Analogs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Somatostatin Analogs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Somatostatin Analogs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Somatostatin Analogs Sales Value (2021-2032)
  21. 6.9.2 South America Somatostatin Analogs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Somatostatin Analogs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Somatostatin Analogs Sales Value Share by Country, 2025 VS 2032
7 Somatostatin Analogs Country-level Sales and Value Analysis
  1. 7.1 Global Somatostatin Analogs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Somatostatin Analogs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Somatostatin Analogs Sales by Country (2021-2032)
  4. 7.3.1 Global Somatostatin Analogs Sales by Country (2021-2026)
  5. 7.3.2 Global Somatostatin Analogs Sales by Country (2027-2032)
  6. 7.4 Global Somatostatin Analogs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Somatostatin Analogs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Somatostatin Analogs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Somatostatin Analogs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Somatostatin Analogs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Somatostatin Analogs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Somatostatin Analogs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Somatostatin Analogs Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Peptron
  8. 8.2.1 Peptron Company Information
  9. 8.2.2 Peptron Business Overview
  10. 8.2.3 Peptron Somatostatin Analogs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Peptron Somatostatin Analogs Product Portfolio
  12. 8.2.5 Peptron Recent Developments
  13. 8.3 Ipsen Biopharmaceutical
  14. 8.3.1 Ipsen Biopharmaceutical Company Information
  15. 8.3.2 Ipsen Biopharmaceutical Business Overview
  16. 8.3.3 Ipsen Biopharmaceutical Somatostatin Analogs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Ipsen Biopharmaceutical Somatostatin Analogs Product Portfolio
  18. 8.3.5 Ipsen Biopharmaceutical Recent Developments
  19. 8.4 Chiasma
  20. 8.4.1 Chiasma Company Information
  21. 8.4.2 Chiasma Business Overview
  22. 8.4.3 Chiasma Somatostatin Analogs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Chiasma Somatostatin Analogs Product Portfolio
  24. 8.4.5 Chiasma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Somatostatin Analogs Value Chain Analysis
  2. 9.1.1 Somatostatin Analogs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Somatostatin Analogs Sales Mode & Process
  6. 9.2 Somatostatin Analogs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Somatostatin Analogs Distributors
  9. 9.2.3 Somatostatin Analogs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst